Electrocardiographic findings of palonosetron in cancer patients
Electrocardiographic findings of palonosetron in cancer patients
复制标题
DOI：
10.1007/s00520-011-1226-5
复制
发表时间：
2012-07-01
影响因子：
3.1
通讯作者：
Yucel, Idris
中科院分区：
文献类型：
--
作者：
Gonullu, Guzin;Demircan, Sabri;Yucel, Idris
恶心和呕吐是癌症患者化疗期间和化疗后出现的主要问题之一。最近开发的5-HT3拮抗剂已被证明比以前的药物更有效。几项研究表明，这些药物会引起某些心电图变化。我们的目的是评估新的5-HT3拮抗剂之一帕洛诺司琼引起的心电图变化。我们的研究共包括50名确诊为实体器官肿瘤并接受化疗的患者。帕洛诺司琼输注前行12导联心电图检查。随后分别于输注帕洛诺司琼后30、60、90分钟行心电图。测量输注前后动脉血压。评价各心电图的PR、QRS、QT、QTmax、QTmin、QTd、Pmax、Pmin、Pd、QTc、QTcmax、QTcmin、QTcd值。我们没有发现帕洛诺司琼输注前后（30min）收缩压和舒张压之间有显著相关性（p < 0.05）。然而，有统计学意义的心率下降（p = 0.000）。心电图结果的评估显示，从0分钟与30分钟、60分钟和90分钟的比较可以看出，PR距离明显延长。QRS、QT、QTmax、QTmin、QTd、Pmax、Pmin、Pd、QTc、QTcmax、QTcmin、QTcd值差异无统计学意义（p < 0.05）。在这项研究中，我们发现帕洛诺司琼没有引起任何严重的节律障碍或症状性心电图改变。我们的结论是帕洛诺司琼的止吐是安全的。
Nausea and vomiting are among the major problems occurring during and after the chemotherapy treatments of cancer patients. The recently developed 5-HT3 antagonists have proved much more effective than former agents. Several studies have shown that these agents cause certain ECG changes. We aimed to evaluate the ECG changes caused by palonosetron, one of the new 5-HT3 antagonists.Our study includes a total of 50 patients diagnosed with solid-organ tumors receiving chemotherapy. The patients were applied 12-lead ECG before palonosetron infusion. Afterwards, subsequent ECGs were applied on the 30th, 60th, and 90th minutes following the infusion of palonosetron. Arterial blood pressure was measured before and after the infusion. PR, QRS, QT, QTmax, QTmin, QTd, Pmax, Pmin, Pd, QTc, QTcmax, QTcmin, and QTcd values were evaluated for each ECG.We did not detect significant correlations between the systolic and diastolic blood pressures before and after (30 min) palonosetron infusion (p > 0.05). However, there was a statistically significant decrease in heart rate (p = 0.000). The evaluation of ECG findings revealed that there was a significant prolongation in PR distance, as shown by the comparisons of 0 min with 30, 60, and 90 min. On the other hand, there was no significant difference in QRS, QT, QTmax, QTmin, QTd, Pmax, Pmin, Pd, QTc, QTcmax, QTcmin, and QTcd values (p > 0.05).In this study, we revealed that palonosetron did not cause any severe rhythmic disorders or symptomatic ECG changes. We concluded that it could be safe to administer palonosetron antiemetically.